Exco InTouch Shortlisted for the Best Technological Development in Clinical Trials 2014 SCRIP Award
News Oct 04, 2014
Exco InTouch has announced that its mDNA® technology project team have been shortlisted for the “Best Technological Development in Clinical Trials” category for the 2014 SCRIP Awards.
The innovative technology is a diagnostic and data handling tool providing secure and anonymous data communication and storage for clinical trials. Through interrogating the device in use, mDNA® facilitates a BYOD (Bring Your Own Device) approach in clinical research, as well as enabling content to be displayed appropriately, enhancing the familiarity and usability for each trial participant. Moreover, mDNA® supports essential data security and privacy controls by segregating Personally Identifiable Information (PII) in accordance EU Data Protection, Safe Harbor, and HIPAA data protection regulations.
As a leading electronic Clinical Outcomes Assessment (eCOA) and electronic Patient Reported Outcomes (ePRO) provider, Exco InTouch is committed to developing novel technology, like mDNA®, and to driving innovation to improve clinical trials to the benefit of both clinicians and patients. Exemplifying the company’s commitment to technological development, Exco InTouch recently unveiled further innovation by announcing that it is the only eCOA provider to have published native apps on all major mobile operating platforms, including iOS, Android and Windows8.
Tim Davis, CEO and founder of Exco InTouch commented: “We are delighted to have been shortlisted for this award. Indeed, we have an established track record for driving technological innovation in the field of digital data capture and patient engagement solutions in order to optimize efficiencies in clinical trials to the benefit of both clinicians and patients. Our proprietary mDNA® technology is a prime example of this and we are pleased that it has received such industry recognition. We look forward to continuing to take a lead in this critically important area”.
PPD and Quotient Sciences Form Innovative Partnership to Accelerate Pediatric Drug DevelopmentNews
Will shorten timelines, reduce costs and simplify contracting process in pediatric programs.READ MORE
Safety and Efficacy of MERS Treatment Confirmed in Phase I TrialNews
An experimental treatment developed from cattle plasma for Middle East respiratory syndrome (MERS) coronavirus infection shows broad potential, according to a small clinical trial. The treatment, SAB-301, was safe and well tolerated by healthy volunteers, with only minor reactions documented.READ MORE